Catalent to Manufacture Opiod Discontinuation Treatment Iofexidine

Catalent Pharma Solutions has announced it has entered an exclusive agreement with US WorldMeds for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilit …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals